Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Seroflo 125 - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Seroflo 125

Approved

STANDARD

Seroflo 125

Cipla Ltd. (Unit II)🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 7d288a8e7cad9ca7
Company: Cipla Ltd. (Unit II)
Type: Standard

Approval Details

Approval Id: 7d288a8e7cad9ca7
Drug Approval Philippines Name: Seroflo 125
Product Name: Seroflo 125
Registration Number: DRP-10194
Brand Name: Seroflo 125
Generic Name: Salmeterol (As Xinafoate) + Fluticasone Propionate
Dosage Form: Metered Dose Inhaler (CFC Free) (120 doses)
Dosage Strength: 25 mcg/125 mcg per Actuation
Manufacturer: Cipla Ltd. (Unit II)
Importer: Healol Pharma Corporation
Distributor: Healol Pharma Corporation
Issuance Date: 26 October 2021
Expiry Date: 31 January 2027
Pharmacologic Category: Anti-asthma
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

7d288a8e7cad9ca7

Type

Standard

Back to Philippines FDA Approvals